NB300-208 CAMK2A / CaMK II alpha (pThr305) antibody
see related secondary antibodiessee all 39 CAMK2A / CaMK II alpha products
0.1 ml / US$ 465 no delivery possible
Quick Overview
Rabbit anti CAMK2A / CaMK II alpha (pThr305)
Synonyms
CAMKA, KIAA0968, kinase II subunit alpha, CaMK-II subunit alpha, , Calcium/calmodulin-dependent protein kinase type II alpha chain
Product review
Please read our product review about CAMK2A / CaMK II alpha (pThr305): Antibodies to Calmodulin and CaM-kinases.
Product Description
Rabbit anti CAMK2A / CaMK II alpha (pThr305) , Presentation: Aff - Purified. Product is tested for Frozen sections ( C ), Immunoprecipitation ( IP ), Western blot / Immunoblot ( WB )
Properties
| Applications | Frozen sections ( C ), Immunoprecipitation ( IP ), Western blot / Immunoblot ( WB ) |
| Reactivity | Human ( Hu ), Mouse ( Ms ), Rat ( Rt ), Bovine ( Bov ), Chicken ( Chk ), Xenopus ( Xen ) |
| Presentation | Aff - Purified |
| Host | Rabbit |
| Catalog Number | NB300-208 |
| Swiss Prot. No. | Q9UQM7 |
| Quantity | 0.1 ml |
| Price | US$ 465 no delivery possible |
| Delivery | Not USA/Canada |
| Manufacturer | Novus Biologicals Inc. |
| Datasheet | view  NB300-208.pdf |
Datasheet Extract
| Rabbit Polyclonal anti-Calcium/Calmoduiln kinase II [Thr305] | |
| Alternate names | anti-Cam KII antibody, anti-CAMKII antibody |
| Background | CaM KII is an important member of calcium/calmodulin-activated kinase, functioning in neural synaptic stimulation and T-cell receptor signaling. CaM KII has catalytic and regulatory domains. The binding of Ca++/calmodulin to its regulatory domain releases its autoinhibitory effect and activates the kinase. The activated CaM KII further autophosphorylates itself at Thr286 to render the kinase constitutively active. The threonine phosphorylation state of CaM KII can be regulated through PP1/PKA. PP1 (protein phosphatase 1) dephosphorylates phospho-CaM KII at Thr286. On the other hand, PKA (protein kinase A) prevents this phosphorylation process through its inhibitory effect on PP1. |
| Immunogen | NB 300-208 was raised against a synthetic phosphopeptide corresponding to amino acid residues surrounding the phosphorylated Thr305 of CAM KII. This sequence is identical in human, rat, mouse, drosophila, and limulus and in alpha, beta, and delta forms. Swiss Num.: Q9UQM7 |
| Format | Purification: Immunogen affinity purified Purity: Immunogen affinity purified |
| Applications | ELISA , immunohistochemistry 1:100, immunoprecipitation , Western Blot 1:1000 |
| Specificity | Species: Detects rat, mouse, human, bovine, chicken and xenopus. Immunolabeling is absent in homogenate of brain from T305D mutant mice. |
| Storage | Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles. |
| References | 1. Elgersma, et al. Neuron, 36: 493-505. 2002 |
12 Secondary Antibodies
| Catalog No. | Name / Host | Presentation | Reactivity | ||||
|---|---|---|---|---|---|---|---|
| R1364B | Rabbit IgG (H&L) | ||||||
| Goat | Biotin | 2 mg / US$ 295 | |||||
| R1364F | Rabbit IgG (H&L) | ||||||
| Goat | FITC | 2 mg / US$ 285 | |||||
| R1364T | Rabbit IgG (H&L) | ||||||
| Goat | TRITC | 2 mg / US$ 285 | |||||
| R1364TR | Rabbit IgG (H&L) | ||||||
| Goat | Texas Red | 2 mg / US$ 295 | |||||
| R1364HRP | Rabbit IgG (H&L) | ||||||
| Goat | HRP | 2 mg / US$ 295 | |||||
| R1364AP | Rabbit IgG (H&L) | ||||||
| Goat | AP | 1 mg / US$ 325 | |||||
| R1458C2 | Rabbit IgG (H&L) multi-species ads. | ||||||
| Goat | Cy2 | 1 mg / US$ 445 | |||||
| R1458C3 | Rabbit IgG (H&L) multi-species ads. | ||||||
| Goat | Cy3 | 1 mg / US$ 445 | |||||
| R1458C35 | Rabbit IgG (H&L) multi-species ads. | ||||||
| Goat | Cy3.5 | 1 mg / US$ 445 | |||||
| R1458C5 | Rabbit IgG (H&L) multi-species ads. | ||||||
| Goat | Cy5 | 1 mg / US$ 445 | |||||
| R1458C55 | Rabbit IgG (H&L) multi-species ads. | ||||||
| Goat | Cy5.5 | 1 mg / US$ 445 | |||||
| R1427R | Rabbit IgG (H&L) F(ab')2 Fragment multi-species ads. | ||||||
| Donkey | PE | 1 ml / US$ 455 | |||||
Click here to see all secondary antibodies for 'NB300-208 CAMK2A / CaMK II alpha (pThr305)'.
